Merck Sharp + Dohme Corp.

Msd R&d (china) Co., Ltd.

Merck + Co., Inc.

Merck Canada Inc.

Merck Sharp & Dohme LLC

Msd R&d Co., Ltd.

Qiaolin Deng

Amjad Ali

Jared N Cumming

Thomas H Graham

Rongze Kuang

Yeon-Hee Lim

Anandan Palani

Kun Liu

Peter J Sinclair

Michael Man-Chu Lo

Zhijian Lu

Elisabetta Bianchi

Umar Faruk Mansoor

Christopher Francis Thompson

Christopher W Plummer

Andrew William Stamford

Ravi P Nargund

Younong Yu

Pauline C Ting

Ping Liu

Duane E DeMong

Antonello Pessi

Xianhai Huang

Melissa S Egbertson

Dong Xiao

Michael Berlin

Jianming Bao

Ling Tong

Tomi K Sawyer

Michael T Rudd

Christopher W Boyce

Robert D Mazzola, Jr

David M Tellers

Timothy J Henderson

Xiaolei Gao

Cameron James Smith

Neville J Anthony

Michael D Altman

Thomas Allen Miller

Joseph Michael Kelly

Alan B Northrup

Daniel Guay

Thomas Joseph Tucker

Michelle R Machacek

Songnian Lin

Yonglian Zhang

Huijun Wang

Federica Orvieto

Matthew A Larsen

Nazia Quraishi

Heping Wu

Jianping Pan

Gayle E Taylor

Paul E Carrington

Elisabeth Hennessy

Aaron Sather

Paul Tempest

Junying Zheng

Sandra Lee Knowles

John J Acton, Iii

Nicolas Zorn

Fengqi Zhang

Walter Won

Scott T Harrison

Gang Zhou

Chunsing Li

Oleg B Selyutin

Jae-Hun Kim

Gioconda V Gallo

Ronald Dale Ferguson, Ii

Meng Na

Brian M Andresen

Rajan Anand

Tao Yu

John Michael Ellis

Jayaram R Tagat

Jonathan B Grimm

Takao Suzuki

Yi-Heng Chen

Wei Zhou

Liping Wang

Zhaoyang Meng

Anthony Donofrio

Yuping Zhu

Kaleen Konrad Childers

Hong Li

Yuan Liu

Kerrie Spencer

Edward Metzger

Joel S Robichaud

Julianne A Hunt

Chengwei Wu

Eric Thomas Romeo

Kake Zhao

Chunhui Huang

Hongwu Wang

Hyun Chong Woo

David Kim

Byron Dubois

In its many embodiments, the present invention provides certain substituted amino triazolopyrimidine and amino triazolopyrazine compounds of Formula (IA) and Formula (IB): or and pharmaceutically acceptable salts thereof, wherein, R, R, and Rare as defined herein, pharmaceutical compositions comprising one or more such compounds (alone and in combination with one or more other therapeutically active agents), and methods for their preparation and use, alone and in combination with other therapeutic agents, as antagonists of A2a and/or A2b receptors, and their use in the treatment of a variety of diseases, conditions, or disorders that are mediated, at least in part, by the adenosine A2a receptor and/or the adenosine A2b receptor.

Substituted amino triazolopyrimidine and amino triazolopyrazine adenosine receptor antagonists, pharmaceutical compositions and their use

In its many embodiments, the present invention provides certain substituted amino triazolopyrimidine and amino triazolopyrazine compounds of Formula (IA) and Formula (IB): and, and pharmaceutically acceptable salts thereof, wherein, R, n, R, and Rare as defined herein, pharmaceutical compositions comprising one or more such compounds (alone and in combination with one or more other therapeutically active agents), and methods for their preparation and use, alone and in combination with other therapeutic agents, as antagonists of A2a and/or A2b receptors, and their use in the treatment of a variety of diseases, conditions, or disorders that are mediated, at least in part, by the adenosine A2a receptor and/or the adenosine A2b receptor.

In its many embodiments, the present invention provides certain 7-, 8-, and 10-substituted amino triazolo quinazoline derivatives of Formula (I): or a pharmaceutically acceptable salt thereof, wherein ring A, R1, R2, and R4 are as defined herein, pharmaceutical compositions comprising one or more such compounds (alone and in combination with one or more other therapeutic agents), and methods for their preparation and use, alone and in combination with other therapeutic agents, as antagonists of A2a and/or A2b receptors, and their use in the treatment of a variety of diseases, conditions, or disorders that are mediated, at least in part, by the adenosine A2a receptor and/or the adenosine A2b receptor.

7-, 8-, and 10-substituted amino triazolo quinazoline derivatives as adenosine receptor antagonists, pharmaceutical compositions and their use

In its many embodiments, the present invention provides certain 9-substituted amino triazolo quinazoline compounds of the structural Formula (I): and pharmaceutically acceptable salts thereof, wherein, ring A, Rand Rare as defined herein, pharmaceutical compositions comprising one or more such compounds (alone and in combination with one or more other therapeutically active agents), and methods for their preparation and use, alone and in combination with other therapeutic agents, as antagonists of A2and/or A2receptors, and in the treatment of a variety of diseases, conditions, or disorders that are mediated, at least in part, by the adenosine A2receptor and/or the adenosine A2receptor.

9-substituted amino triazolo quinazoline derivatives as adenosine receptor antagonists, pharmaceutical compositions and their use

Long-acting co-agonists of the glucagon and GLP-1 receptors are described.

Long-acting co-agonists of the glucagon and GLP-1 receptors

The present invention is directed to pyrazol-4-yl-pyridine compounds which are allosteric modulators of the M4 muscarinic acetylcholine receptor. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which M4 muscarinic acetylcholine receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which M4 muscarinic acetylcholine receptors are involved.

3-(1H-pyrazol-4-yl)pyridine allosteric modulators of the M4 muscarinic acetylcholine receptor

In its many embodiments, the present invention provides certain 9-substituted amino triazolo quinazoline compounds of the structural Formula (I): and pharmaceutically acceptable salts thereof, wherein, ring A, Rand Rare as defined herein, pharmaceutical compositions comprising one or more such compounds (alone and in combination with one or more other therapeutically active agents), and methods for their preparation and use, alone and in combination with other therapeutic agents, as antagonists of A2a and/or A2b receptors, and in the treatment of a variety of diseases, conditions, or disorders that are mediated, at least in part, by the adenosine A2a receptor and/or the adenosine A2b receptor.

Disclosed are compounds of Formula A and Formula A-1, or a salt thereof, and pharmaceutical formulations (pharmaceutical compositions) comprising those compounds, or a salt thereof; wherein 'R', 'R', &#x201c;R&#x201d;, &#x201c;R&#x201d;, and &#x201c;Het&#x201d; are defined herein above, which compounds are believed suitable for use in selectively antagonizing the A2a receptors, for example, those found in high density in the basal ganglia. Such compounds and pharmaceutical formulations are believed to be useful in treatment or management of neurodegenerative diseases, for example, Parkinson's disease, or movement disorders arising from use of certain medications used in the treatment or management of Parkinson's disease. 

Aminopyrazine compounds with A2A antagonist properties

Described are peptide analogs of glucagon, which have been modified to be resistant to cleavage and inactivation by dipeptidyl peptidase IV (DPP-IV) and to increase in vivo half-life of the peptide analog while enabling the peptide analog to have relatively balanced agonist activity at the glucagon-like peptide 1 (GLP-1) receptor and the glucagon (GCG) receptor, and the use of such GLP-1 receptor/GCG receptor co-agonists for treatment of metabolic disorders such as diabetes, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and obesity.

Co-agonists of the glucagon and GLP-1 receptors

Disclosed are compounds of Formula G1: where 'R'. 'R' to &#x201c;R&#x201d;, &#x201c;n&#x201d;, &#x201c;m&#x201d;, &#x201c;p&#x201d;, &#x201c;W&#x201d;, &#x201c;X&#x201d;, &#x201c;Y&#x201d;, and &#x201c;Z&#x201d; are defined herein, which compounds are antagonists of Areceptor. Disclosed herein also are uses of the compounds described herein as antagonists of the A2A receptor in the potential treatment or prevention of neurological disorders and diseases in which Areceptors are involved. Disclosed herein also are pharmaceutical compositions comprising these compounds and uses of these pharmaceutical compositions.

Heterobicyclo-substituted [1,2,4]triazolo[1,5-c]quinazolin-5-amine compounds with A2A anatagonist properties

The invention provides certain thiazole-substituted aminoheteroaryl compounds of the Formula (I) or pharmaceutically acceptable salts thereof, wherein X, X, X, X, Y, Y, Y, Y, and Rare as defined herein. The invention also provides pharmaceutical compositions comprising such compounds, and methods of using the compounds for treating diseases or conditions mediated by Spleen Tyrosine Kinase (Syk). 

Thiazole-substituted aminoheteroaryls as spleen tyrosine kinase inhibitors

Disclosed are compounds of Formula A: (structurally represented) where 'RG1', 'RG2a', &#x201c;RG4&#x201d;, &#x201c;RG5&#x201d;, &#x201c;MG1&#x201d;, &#x201c;n&#x201d; and &#x201c;m&#x201d; are defined herein which compounds are antagonists of A2A receptor. Disclosed herein also are uses of the compounds described herein as antagonists of the A2a receptor in the potential treatment or prevention of neurological disorders and diseases in which A2A receptors are involved. Disclosed herein also are pharmaceutical compositions comprising these compounds and uses of these pharmaceutical compositions. 

[object Object]

Growing community of inventors

Edison, NJ, United States of America

Qiaolin Deng